TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35969830
Drug: Neoadjuvant nivolumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant nivolumab 240 mg once every two weeks ×6 and ipilimumab 1 mg/kg once every six weeks ×2, followed by adjuvant nivolumab 480 mg once every four weeks (nine injections)
Study: 35970164
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no cochlear implant)
Study: 35970714
Drug: Alpha-1 MP
Normalized name: alpha 1-antitrypsin
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-1 MP (60 mg/kg) weekly for 52 weeks
Study: 35970920
Drug: Individualized, heterologous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized, heterologous chimpanzee adenovirus (ChAd68) and self-amplifying mRNA (samRNA)-based neoantigen vaccine in combination with nivolumab and ipilimumab
Study: 35971681
Drug: Smartphone-based automated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smartphone-based automated insulin delivery (AID) using interoperable artificial pancreas system (iAPS) and zone model predictive control (MPC) on an unlocked smartphone for 48 hours.
Study: 35971681
Drug: Smartphone-based automated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smartphone-based automated insulin delivery (AID)
Study: 35971857
Drug: Degarelix administration
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Degarelix administration
Study: 35971951
Drug: Bepirovirsen (75-450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bepirovirsen (75-450 mg single dose; 150-450 mg multiple doses on days 1, 4, 8, 11, 15, and 22)
Study: 35972667
Drug: Laparoscopic hyperthermic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin/mitomycin C
Study: 35972987
Drug: Inhaled Galectin-3
Normalized name: GALECTIN-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Galectin-3 Inhibitor
Study: 35973031
Drug: Empagliflozin, dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin, dosage and duration not available
Study: 35973190
Drug: Sutimlimab (biweekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sutimlimab (biweekly administration for a median of 20.5 weeks)
Study: 35973199
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of enasidenib with azacitidine
Study: 35973199
Drug: Enasidenib monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enasidenib monotherapy after prior hypomethylating agent (HMA) therapy
Study: 35973200
Drug: Pembrolizumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (200 mg every 3 weeks for up to 2 years)
Study: 35973665
Drug: Pralsetinib 400
Normalized name: pralsetinib
DrugBank: Pralsetinib (DB15822)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pralsetinib 400 mg once daily until disease progression, intolerance, consent withdrawal, or investigator's decision.
Study: 35973737
Drug: Dostarlimab (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dostarlimab (500 mg IV every 3 weeks for 4 cycles, then 1000 mg IV every 6 weeks)
Study: 35974320
Drug: Daily alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily alcohol consumption in the third quartile (5.36-11.42 g/day)
Study: 35974874
Drug: Natural procreative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural procreative technology treatment
Study: 35974896
Drug: SARS-CoV-2 antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: SARS-CoV-2 antibodies testing
Study: 35975199
Drug: Multiplexed, baited,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiplexed, baited, targeted proteomics assay for detection of SARS-CoV-2 anti-spike antibody immunocomplex
Study: 35976570
Drug: Brensocatib (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brensocatib (10 mg and 25 mg)
Study: 35976603
Drug: Esaxerenone monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esaxerenone monotherapy (2.5 or 5 mg/day)
Study: 35977532
Drug: Hydroxyurea at
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea at 20 mg/kg/day with dose escalation to maximum tolerated dose (MTD)
Study: 35977756
Drug: Nivolumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab plus rucaparib (nivolumab 480 mg every 4 weeks plus rucaparib 600 mg two times per day)
Study: 35977936
Drug: PRV111 (neoadjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRV111 (neoadjuvant treatment)
Study: 35978403
Drug: Highest value
Normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highest value of two FIT at cutoff 10 μg Hb/g faeces
Study: 35979039
Drug: Stimulant comorbidity
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulant comorbidity
Study: 35979886
Drug: Analytical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analytical treatment interruption (ATI) during the HIV cure-directed trial
Study: 35980235
Drug: osilodrostat (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: osilodrostat (starting dose 2 mg bid; maximum 30 mg bid)
Study: 35980739
Drug: Lumme Quit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumme Quit Smoking app and smartwatch combination
Study: 35980739
Drug: Control arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control arm with 8-week supply of nicotine replacement therapy, 30-minute smoking cessation counseling session, and weekly check-in calls
Study: 35982228
Drug: Good pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Good pain control under analgesic treatment
Study: 35982228
Drug: Poor pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poor pain control despite analgesic treatment
Study: 35982244
Drug: Maternal voice
Normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal voice exposure (twice daily for 20 minutes before oral feeding)
Study: 35982649
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone furoate 200 μg once daily for 14 days
Study: 37733308
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone furoate
Study: 35982669
Drug: Ivermectin 400
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin 400 µg/kg daily for 3 days
Study: 35983024
Drug: Apatinib (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib (250 mg once daily) combined with docetaxel (IV every 3 weeks for four cycles) followed by epirubicin plus cyclophosphamide (IV every 3 weeks for four cycles)
Study: 35983177
Drug: Cerene Cryotherapy
Normalized name: cedrene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerene Cryotherapy Device treatment
Study: 35983331
Drug: mNGS-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: mNGS-guided treatment
Study: 35983331
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (guided by CMT)
Study: 35984091
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment (n = 88; 31%)
Study: 35984091
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment (control group)
Study: 35984611
Drug: Heparin-like effect
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-like effect (HLE) defined as ≥ 20% difference in paired gb/h-SONOCLOT™ traces for activated clotting time (ACT)
Study: 35986100
Drug: Alcohol/drug use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol/drug use
Study: 35986671
Drug: Daily dolutegravir-abacavir-lamivudine
Normalized name: abacavir / dolutegravir / lamivudine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dolutegravir-abacavir-lamivudine
Study: 35986823
Drug: Methylprednisolone dose
Normalized name: MethylPREDNISolone Dose Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone dose
Study: 35987601
Drug: Bioresorbable vascular
Normalized name: acellular tissue engineered vessel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioresorbable vascular scaffold (BVS) treatment
Study: 35987625
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment costs for malaria and pneumonia
Study: 35987625
Drug: Timely treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timely treatment for malaria and pneumonia
Study: 35987704
Drug: Smoking cessation
Normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking cessation pharmacotherapy (7.2% of current smokers)
Study: 35988545
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with obinutuzumab, acalabrutinib, and venetoclax after optional debulking with bendamustine
Study: 35988546
Drug: Mitapivat (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitapivat (5 mg, 20 mg, 50 mg twice daily during a 16-week dose-optimisation period followed by a 24-week fixed-dose period)
Study: 35989865
Drug: Assessment and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assessment and treatment by primary care physicians
Study: 35989865
Drug: Identification of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identification of medication nonadherence
Study: 35989865
Drug: Identification of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identification of drug-drug interactions (DDIs)
Study: 35989924
Drug: Bridging intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bridging intravenous thrombolysis (IVT)
Study: 35989924
Drug: Prior medication
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior medication with Vitamin K antagonists (VKA)
Study: 35990111
Drug: Tele-yoga intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tele-yoga intervention (two one-on-one 30-minute sessions weekly for a total of 12 sessions)
Study: 35992822
Drug: JMT103 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JMT103 at 0.5, 1.0, 2.0, and 3.0 mg/kg every 4 weeks for 3 cycles
Study: 35992943
Drug: Contacts in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contacts in closest proximity to internal capsule
Study: 35993306
Drug: Postneoadjuvant treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postneoadjuvant treatments (e.g., capecitabine, Olaparib)
Study: 35993306
Drug: Type 3
Normalized name: Type 3 H
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type 3 approaches (e.g., circulating tumour DNA)
Study: 35994321
Drug: Active Video
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Video Game-based intervention (12 weekly sessions) with game-based pedometers, PA behavioral coaching, and survivorship navigation discussions.
Study: 35994746
Drug: Maternal RBC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal RBC folate concentrations ≥906 nmol/L
Study: 35995129
Drug: Interventions following
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interventions following a standard treatment algorithm for persistent cerebral desaturation.
Study: 35995696
Drug: Autologous CIK
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous CIK cells therapy combined with Sintilimab and platinum-based doublet chemotherapy
Study: 35996565
Drug: AZD1656 (100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD1656 (100mg twice a day)
Study: 35996930
Drug: Methotrexate and
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate and sulfasalazine (disease-modifying antirheumatic drugs)
Study: 35996930
Drug: Korean patients
Normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Korean patients with PsA requiring biologics
Study: 35998971
Drug: Perioperative mental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative mental health intervention bundle (behavioural activation and medication optimisation)
Study: 35999221
Drug: PfSPZ Vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PfSPZ Vaccine (radiation-attenuated Plasmodium falciparum sporozoites)
Study: 36000222
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron (ferrous sulphate, 120 mg elemental iron)
Study: 36000434
Drug: LDL-C ≥100
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL-C ≥100 mg/dL
Study: 36000434
Drug: LDL-C 70-99
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL-C 70-99 mg/dL
Study: 36000747
Drug: Molecular adsorbent
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Molecular adsorbent recirculating system (MARS) treatment
Study: 36000783
Drug: Professional coaching
Normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Professional coaching (6 monthly sessions)
Study: 36000783
Drug: Delayed intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delayed intervention (6 monthly sessions after 6 months)
Study: 36000794
Drug: Neoadjuvant apalutamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant apalutamide 240 mg once daily for 12 weeks
Study: 36001108
Drug: Fluconazole 400
Normalized name: fluconazole 400 MG in 200 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 400 mg on day 10 and fluconazole 200 mg once daily on days 11-23, with a single oral dose of fedratinib 100 mg on day 18
Study: 36001108
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of fedratinib 100 mg on day 1
Study: 36001228
Drug: Camrelizumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab (200 mg intravenously every 3 weeks)
Study: 36001228
Drug: Palliative SBRT
Normalized name: Various pain palliation radiopharmaceuticals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palliative SBRT (30-50 Gy delivered daily over five fractions per week)
Study: 36001228
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of palliative SBRT and camrelizumab
Study: 36001750
Drug: High-dose glucagon
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose glucagon (1.5 ng/kg/min, t = 270-450 min)
Study: 36001750
Drug: Low-dose glucagon
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose glucagon (0.65 ng/kg/min, t = 0-270 min)
Study: 36002226
Drug: Epidural infusion
Normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusion of bupivacaine
Study: 36002243
Drug: Histotripsy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histotripsy treatment for hepatic tumors
Study: 36002847
Drug: Preference-concordant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preference-concordant treatment decisions
Study: 36002847
Drug: Attributing a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attributing a lot of influence to treatment impact on recreation
Study: 36004765
Drug: Micronized purified
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized purified flavonoid fraction (MPFF) added to conservative treatment
Study: 36005642
Drug: Multispecies Probiotic
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multispecies Probiotic Treatment
Study: 36006468
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose tolerance test (OGTT) with a 75-g glucose dose
Study: 36006468
Drug: Energy metabolism
Normalized name: Walgreens Vitamin B12 Energy Metabolism 100mcg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy metabolism response to OGTT
Study: 36007963
Drug: Trametinib (T)
Normalized name: Trametinib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Trametinib (T) 2 mg/day orally starting 1 week prior to durvalumab (D) 1500 mg intravenously every 4 weeks
Study: 36007963
Drug: Tumor tissue
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumor tissue flow cytometry at baseline (BL) and early on-treatment (OT) at week 4
Study: 36008193
Drug: Intravesical pembrolizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical pembrolizumab (1-5 mg/kg for 2 hours)
Study: 36008198
Drug: 24-h levodopa-carbidopa
Normalized name: carbidopa / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-h levodopa-carbidopa intestinal gel (LCIG)
Study: 36008198
Drug: 16-h levodopa-carbidopa
Normalized name: carbidopa / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16-h levodopa-carbidopa intestinal gel (LCIG)
Study: 36011453
Drug: Professional Pharmaceutical
Normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Professional Pharmaceutical Service intervention
Study: 36012885
Drug: Patient-reported treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-reported treatment experience
Study: 36013098
Drug: Novel implant
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel implant system with low-speed (50 rpm) site preparation instruments used without irrigation and tri-oval, tapered implant.
Study: 36015302
Drug: TDM arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TDM arm (therapeutic drug monitoring)
Study: 36015771
Drug: iPhone App
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: iPhone App for detecting prefrailty and sarcopenia syndromes, using sit-to-stand muscle power measured through a slow-motion video analysis mobile application in combination with muscle mass (calf circumference or upper mid-arm circumference).
Study: 36016106
Drug: Ormutivimab +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ormutivimab + vaccine
Study: 36016106
Drug: HRIG +
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRIG + vaccine
Study: 36017088
Drug: Evolocumab (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab (140 mg subcutaneous) on top of 10 mg/day rosuvastatin
Study: 36017315
Drug: Insulin-induced hypoglycemia
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-induced hypoglycemia (2mmol/l: 36mg/dl) in control subjects
Study: 36017315
Drug: Insulin-induced hypoglycemia
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-induced hypoglycemia (2mmol/l: 36mg/dl) in T2D subjects
Study: 36028065
Drug: Proton radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton radiation therapy (proton-RT)
Study: 36028065
Drug: Conventional radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional radiation therapy (not explicitly mentioned in the study but referenced for comparison)
Study: 36028446
Drug: Dupilumab 200/300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab 200/300 mg every 2 weeks for 52 weeks
Study: 36028757
Drug: Reduced-toxicity conditioning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced-toxicity conditioning regimen (RTC) using intravenous busulfan (3.2 mg/kg/d for 4 days) and fludarabine (30 mg/m2); specific dosage and duration provided.
Study: 36028895
Drug: Cyclin-dependent kinase
Normalized name: Cyclin-dependent kinase (CDK) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclin-dependent kinase 4 and 6 inhibitors combined with endocrine therapy
Study: 36029527
Drug: ABBV-383 (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABBV-383 (administered intravenously over 1-2 hours once every 3 weeks)
Study: 36029527
Drug: ABBV-383 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABBV-383 (60 mg dose in dose expansion cohort)
Study: 36029527
Drug: ABBV-383 (≥
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABBV-383 (≥ 40 mg in dose escalation plus dose expansion cohorts)
Study: 36029725
Drug: Medication administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medication administration based on CPIC Level A evidence.
Study: 36030342
Drug: Analgesics (including
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesics (including opioids, gabapentinoids, and paracetamol) dispensed to adolescents from age 15
Study: 36030342
Drug: Benzodiazepines and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzodiazepines and z-hypnotics
Study: 36030342
Drug: Overall prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall prescription drugs
Study: 36031093
Drug: Infliximab (IFX),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (IFX), median initial dose 9.9 mg/kg
Study: 36031390
Drug: Very early
Normalized name: Primula veris extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very early antiretroviral treatment
Study: 36034306
Drug: Cognitive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive treatment with Brainer and physical training with jDome
Study: 36034306
Drug: Cognitive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive treatment with Brainer and physical training with a classic bicycle
Study: 36034411
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment (initiating bevacizumab or corticosteroids treatment within three months after RN diagnosis)
Study: 36034411
Drug: Watch-and-wait policy
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Watch-and-wait policy (no early treatment)